SCHEMBL20487124

SCHEMBL20487124

CCc1ccc(C#Cc2cc(C(=O)OC)ccc2N)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
GLA P06280 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
ATM Q13315 1/20 0.46
LOXL2 Q9Y4K0 2/20 0.44
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
PTPN11 Q06124 1/20 0.43
TP53 P04637 1/20 0.42
LNPEP Q9UIQ6 6/20 0.42
ACACB O00763 1/20 0.42
ERAP2 Q6P179 2/20 0.41
TDP1 Q9NUW8 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20488208 0.91 HPGD (0.44) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL20487128 0.90 MAPT (0.51) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL20487495 0.86 TDP1 (0.51) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL20488212 0.85 CA1 (0.53) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL23252136 0.85 ALDH1A1 (0.49) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL18712260 0.83 PTPN11 (0.58) MAPTALDH1A1HPGDLOXL2PTPN11
SCHEMBL23227968 0.83 LOXL2 (0.40) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL20487479 0.82 HDAC1 (0.60) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL20487893 0.82 CASP3 (0.56) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL20488510 0.82 LNPEP (0.38) MAPTALDH1A1KDM4EGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-05-01 US disclosed
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US disclosed
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US disclosed
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-20 US disclosed
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-20 US disclosed
WO-2018160967-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 MAPT 2523/4885ALDH1A1 3459/4885KDM4E 978/4885
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase MELK, HIPK1, HIPK3 MAPT 3092/4885ALDH1A1 2911/4885KDM4E 1151/4885
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 MAPT 2523/4885ALDH1A1 3459/4885KDM4E 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.